THE COST-EFFECTIVENESS OF SEQUENTIAL FIRST- AND SECOND-LINE TREATMENTS IN METASTATIC RENAL CELL CARCINOMA USING REAL-WORLD DATA AND A PATIENT-LEVEL SIMULATION MODEL

被引：0
|
作者：
de Groot, S. [1 ]
Blommestein, H. [1 ]
Redekop, W. [1 ]
Oosterwijk, E. [2 ]
Kiemeney, L. [2 ]
Uyl-de Groot, C. [1 ]
机构：
[1] Erasmus Univ, Rotterdam, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1625
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A587 / A587
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF AFATINIB AND ERLOTINIB AS SECOND-LINE TREATMENTS FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG IN CHINA
    Zhu, J.
    Ye, M.
    Fu, J.
    Wu, B.
    Chu, Y.
    Zhao, Y.
    Zhang, Y.
    Kuo, D.
    Su, B.
    VALUE IN HEALTH, 2017, 20 (09) : A442 - A442
  • [32] Real-World Effectiveness of Second-Line Therapies for Metastatic Non-Small Cell Lung Cancer
    Bazhenova, L.
    Cai, B.
    Gentile, D.
    Kari, G.
    Feinberg, B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E22 - E22
  • [33] Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
    Heng, Daniel Y.
    Signorovitch, James
    Swallow, Elyse
    Li, Nanxin
    Zhong, Yichen
    Qin, Paige
    Zhuo, Daisy Y.
    Wang, Xufang
    Park, Jinhee
    Stergiopoulos, Sotirios
    Kollmannsberger, Christian
    PLOS ONE, 2014, 9 (12):
  • [34] Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
    Cromwell, Ian
    van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2097 - 2103
  • [35] Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study
    Daneels, Willem
    Rosskamp, Michael
    Macq, Gilles
    Saadoon, Estabraq Ismael
    De Geyndt, Anke
    Offner, Fritz
    Poirel, Helene A.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Nunez, S. M.
    Godoy, J., I
    Cardona, A. F.
    Otero, J. M.
    Lujan, M.
    Lopera, D.
    Carranza, H.
    Spath, A.
    Gis, P. R.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [37] COST-EFFECTIVENESS OF PAZOPANIB VERSUS SUNITINIB AND BEVACIZUMAB ASSOCIATED TO INTERFERON ALPHA AS FIRST LINE TREATMENTS FOR METASTATIC RENAL CELL CARCINOMA
    Pepe, C.
    Paladini, L.
    Sedlmayer, C.
    Machado, M.
    VALUE IN HEALTH, 2012, 15 (04) : A218 - A218
  • [38] First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) : 1112 - 1118
  • [39] Real-World Effectiveness and Safety Profile of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer
    Ganti, Apar Kishor
    Allan, Victoria
    Prince, Patricia
    Estrin, Adina
    Gautam, Nileesa
    Merola, Dave
    Boccuti, Anne
    Rengarajan, Badri
    Baratta, Cristina
    Li, Wenyan
    Cao, Yanyan
    Poole, Elizabeth M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E50 - E51
  • [40] Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Yang, Fan
    Fu, Yu
    Kumar, Arun
    Chen, Mingsheng
    Si, Lei
    Rojanasarot, Sirikan
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (15)
12345